| Literature DB >> 29695756 |
Laura Mary1, Amélie Piton2,3, Elise Schaefer4, Francesca Mattioli5,6, Elsa Nourisson1, Claire Feger1, Claire Redin5,6, Magali Barth7, Salima El Chehadeh4,8, Estelle Colin7, Christine Coubes9, Laurence Faivre8, Elisabeth Flori4, David Geneviève9, Yline Capri10, Laurence Perrin10, Jennifer Fabre-Teste10, Dana Timbolschi4, Alain Verloes10, Robert Olaso11, Anne Boland11, Jean-François Deleuze11, Jean-Louis Mandel1,5,6, Bénédicte Gerard1, Irina Giurgea12,13.
Abstract
High-throughput sequencing (HTS) of human genome coding regions allows the simultaneous screen of a large number of genes, significantly improving the diagnosis of non-syndromic intellectual disabilities (ID). HTS studies permit the redefinition of the phenotypical spectrum of known disease-causing genes, escaping the clinical inclusion bias of gene-by-gene Sanger sequencing. We studied a cohort of 903 patients with ID not reminiscent of a well-known syndrome, using an ID-targeted HTS of several hundred genes and found de novo heterozygous variants in TCF4 (transcription factor 4) in eight novel patients. Piecing together the patients from this study and those from previous large-scale unbiased HTS studies, we estimated the rate of individuals with ID carrying a disease-causing TCF4 mutation to 0.7%. So far, TCF4 molecular abnormalities were known to cause a syndromic form of ID, Pitt-Hopkins syndrome (PTHS), which combines severe ID, developmental delay, absence of speech, behavioral and ventilation disorders, and a distinctive facial gestalt. Therefore, we reevaluated ten patients carrying a pathogenic or likely pathogenic variant in TCF4 (eight patients included in this study and two from our previous ID-HTS study) for PTHS criteria defined by Whalen and Marangi. A posteriori, five patients had a score highly evocative of PTHS, three were possibly consistent with this diagnosis, and two had a score below the defined PTHS threshold. In conclusion, these results highlight TCF4 as a frequent cause of moderate to profound ID and broaden the clinical spectrum associated to TCF4 mutations to nonspecific ID.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29695756 PMCID: PMC6018712 DOI: 10.1038/s41431-018-0096-4
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246